Iduna confirmed the association of KRAS mutations with the EGFR resistance phenotype, demonstrating that KRAS wild-type status is a clinical biomarker for targeted therapy of NSCLC (54). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.